Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)

BACKGROUND: We conducted a phase II trial to evaluate the efficacy of dasatinib, a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). METHODS: Eligibility requirements were Karnofsky performance status ≥60%; no concurrent hepatic enzyme-inducing anticonvulsants; p...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Udgivet i:	Neuro Oncol
Main Authors:	Lassman, Andrew B., Pugh, Stephanie L., Gilbert, Mark R., Aldape, Kenneth D., Geinoz, Sandrine, Beumer, Jan H., Christner, Susan M., Komaki, Ritsuko, DeAngelis, Lisa M., Gaur, Rakesh, Youssef, Emad, Wagner, Henry, Won, Minhee, Mehta, Minesh P.
Format:	Artigo
Sprog:	Inglês
Udgivet:	Oxford University Press 2015
Fag:	Clinical Investigations
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5762006/ https://ncbi.nlm.nih.gov/pubmed/25758746 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov011
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)

Lignende værker